Erratum: Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial (Journal of the National Cancer Institute (2015) 107:11 (djv248) DOI: 10.1093/jnci/djv248);Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: A phase III randomized clinical trial

Journal of the National Cancer Institute

Volumn 107, Issue 11, 2015, Pages

  Allegra, Carmen J ^a,b   Yothers, Greg ^a,c   O'Connell, Michael J ^a   Beart, Robert W ^a,d   Wozniak, Timothy F ^a,e   Pitot, Henry C ^a,f   Shields, Anthony F ^a,g   Landry, Jerome C ^a,h   Ryan, David P ^a,i   Arora, Amit ^a,j   Evans, Lisa S ^a,k   Bahary, Nathan ^a,l   Soori, Gamini ^a,m   Eakle, Janice F ^a,n   Robertson, John M ^a,o   Moore, Dennis F ^a,p   Mullane, Michael R ^a,q   Marchello, Benjamin T ^a,r   Ward, Patrick J ^a,s   Sharif, Saima ^a   Roh, Mark S ^a,t,x   Wolmark, Norman ^a,u,v,w   more..

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Glendale Memorial Hospital and Health Center   (United States)

^e CHRISTIANA CARE HEALTH SYSTEM   (United States)

^f MAYO CLINIC   (United States)

^g ALLIANCE   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ SWOG Operations   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ECOG ACRIN   (United States)

^l MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^m KAISER PERMANENTE   (United States)

ⁿ FORSYTH MEDICAL CENTER   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^q Florida Cancer Specialists   (United States)

^r Beaumont Hospital System   (United States)

^s Cancer Center of Kansas   (United States)

^t Stroger Hospital Chicago MU NCORP   (United States)

^u Montana Cancer Consortium   (United States)

^v Oncology Hematology Care   (United States)

^w UNIVERSITY OF FLORIDA   (United States)

^x ALLEGHENY GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ANAL PAIN; ANUS DISEASE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SENSORY NEUROPATHY; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOADJUVANT THERAPY; PROCEDURES; RECTAL NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84981313429     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw057     Document Type: Erratum

References (34)

1. Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014. CA Cancer J Clin. 2014;64(5):9-29.
2. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331(8):502-507.
3. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
4. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
5. Glen H, Cassidy J. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial. Expert Rev Anticancer Ther. 2008;8(4):547-551.
6. Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology. 2000;14(9):1297-1306.
7. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4):291-297.
8. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5(10):2948-2953.
9. Bosset J, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-1123.
10. Gerard J, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-4625.
11. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-1933.
12. Roh MS, Colangelo LH, O'Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124-5130.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-2947.
14. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
15. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21(11):2059-2069.
16. deGramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33(2):214-219.
17. Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorourcil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol. 2003;21(14):2703-2707.
18. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer. 1999;35(9):1338-1342.
19. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768-3774.
20. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(10):3109-3116.
21. NCT00058474 NSABP Protocol R-04. https://clinicaltrials. gov/ct2/show/NCT0 0058474?term=NCT00058474&rank=1. Accessed August 24, 2015.
22. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer. 1978;37(5):849-857.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
25. Cox DR. Regression models and life-tables. J Royal Stat Soc Series B. 1972;34(2):187-220.
26. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927-1934.
27. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched pair analysis. Int J Radiat Oncol Biol Phys. 2006;66(5):1378-1383.
28. Ramani VS, Myint AS, Montazeri A, et al. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine. Colorectal Dis. 2010;12(Suppl 2):37-46.
29. Yothers G, Ganz PA, Lopa SH, et al. Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: results of NSABP R-04. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol. 2012;30:4 (Suppl);Abstract 391.
30. Ganz P, Lopa SH, Yothers G, et al. Comparative effectiveness of sphinctersparing surgery versus abdomino-peritoneal resection in rectal cancer: patient-reported outcomes from NSABP R-04. J Clin Oncol. 2012;30(Suppl);A bstract 3545.
31. Gérard J, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638-1644.
32. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773-2780.
33. Schmoll H, Haustermans K, Jay Price T, et al. Preoperative chemotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: first results of the PETACC-6 randomized phase III trial. J Clin Oncol. 2013;31(Suppl):Abstract 3531.
34. Rödel C, Liersch T, Becker H, et al. Preoperative chemotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomized phase 3 trial. Lancet Oncol. 2012;13(7):679-687.